The 103Pd-DOTMP complex for conversion electron and Auger electron therapy of bone metastatic tumor cells
Abstract
The radionuclide palladium-103 ( ¹⁰³ Pd) has significant potential for use in targeted conversion electron and Auger electron radionuclide therapy. In this study, we synthesized a complex of ¹⁰³ Pd with the macrocyclic ligand DOTMP (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylenephosphonic acid). In the complex, the Pd ²⁺ ions are coordinated by the macrocyclic nitrogen and phosphonate oxygen atoms. While ¹⁰³ Pd remains stably bound to the ligand, our results indicate that approximately 10% of the decay product, 103m Rh, is released from the [ ¹⁰³ Pd]Pd-DOTMP complex in PBS buffer. We evaluated the cytotoxicity of [ ¹⁰³ Pd]Pd-DOTMP and compared it with those of [ ¹⁷⁷ Lu]Lu-DOTMP, which emits β ⁻ particles, and [ ¹⁶¹ Tb]Tb-DOTMP, which emits both β ⁻ particles and Auger electrons. Since DOTMP complexes do not exhibit internalization and lack nuclear localization within cells, the cytotoxic effect of [ ¹⁰³ Pd]Pd-DOTMP is significantly lower than that of DOTMP labeled with the beta emitters ¹⁷⁷ Lu and ¹⁶¹ Tb, which emit β ⁻ particles over a longer range.
Related
- From metastatic disease to no evidence of disease after conversion liver surgery in advanced gastric cancer with liver metastases: A case report.
- AGE-related efficacy and safety of darolutamide triplet therapy in metastatic hormone-sensitive prostate cancer: are we ready for routine clinical practice?
- Symptom burden, Psychosocial Distress, Resilience and Health-Related Quality of Life in Women with Metastatic Breast Cancer Receiving Contemporary Systemic Therapy
- Efficacy and Safety of ramucirumab Combined With Nab‐paclitaxel, Lobaplatin, and S‐1 in Conversion Therapy for Unresectable Advanced Gastric Cancer: Preliminary Results of Conversion Therapy Cohort of RNPLS‐01 Trial
- Stereotactic body radiation therapy enriches mediators of humoral immune activity in metastatic renal cell carcinoma.
BibTeX
@article{annamalaisamy2026103pddotmp,
title = {{The 103Pd-DOTMP complex for conversion electron and Auger electron therapy of bone metastatic tumor cells}},
author = {Geeva Prasanth Annamalaisamy and Magda Piątkowska and Monika Łyczko and Katarzyna Zawadzka and Ulli Köster and Aleksander Bilewicz},
journal = {Scientific Reports},
year = {2026},
month = oct,
doi = {10.1038/s41598-026-75359-6},
url = {https://www.nature.com/articles/s41598-026-75359-6},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - The 103Pd-DOTMP complex for conversion electron and Auger electron therapy of bone metastatic tumor cells
AU - Geeva Prasanth Annamalaisamy
AU - Magda Piątkowska
AU - Monika Łyczko
AU - Katarzyna Zawadzka
AU - Ulli Köster
AU - Aleksander Bilewicz
PY - 2026
DA - 2026/10/09
JO - Scientific Reports
DO - 10.1038/s41598-026-75359-6
UR - https://www.nature.com/articles/s41598-026-75359-6
AB - The radionuclide palladium-103 ( ¹⁰³ Pd) has significant potential for use in targeted conversion electron and Auger electron radionuclide therapy. In this study, we synthesized a complex of ¹⁰³ Pd with the macrocyclic ligand DOTMP (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylenephosphonic acid). In the complex, the Pd ²⁺ ions are coordinated by the macrocyclic nitrogen and phosphonate oxygen atoms. While ¹⁰³ Pd remains stably bound to the ligand, our results indicate that approximately 10% of the decay product, 103m Rh, is released from the [ ¹⁰³ Pd]Pd-DOTMP complex in PBS buffer. We evaluated the cytotoxicity of [ ¹⁰³ Pd]Pd-DOTMP and compared it with those of [ ¹⁷⁷ Lu]Lu-DOTMP, which emits β ⁻ particles, and [ ¹⁶¹ Tb]Tb-DOTMP, which emits both β ⁻ particles and Auger electrons. Since DOTMP complexes do not exhibit internalization and lack nuclear localization within cells, the cytotoxic effect of [ ¹⁰³ Pd]Pd-DOTMP is significantly lower than that of DOTMP labeled with the beta emitters ¹⁷⁷ Lu and ¹⁶¹ Tb, which emit β ⁻ particles over a longer range.
SN - 2045-2322
ER -